🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for PD

Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753n/a2 sites📍 Nanjing📍 Nanjing Zhongda Hospital Effects of Vagal Nerve Stimulation on Leg Muscle Activity and Posture in Parkinson's Disease NCT07226284NA1 site📍 Minneapolis University of Minnesota · Tests: Vagal nerve stimulation, No intervention A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) NCT07373964Phase 21 site📍 Shenyang China Medical University, China · Tests: Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic. NCT07207096n/a1 site📍 London St. Mary's University, Twickenham · Tests: complementary medicine Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease NCT07536542NA1 site📍 Ankara Ankara University · Tests: Dual-Task Training LFP-based Parameter Prediction in DBS for Parkinson's Disease NCT07485621n/a1 site📍 Leuven Loes Laurijssen A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) NCT06657768Phase 113 sites📍 Los Alamitos📍 Lady Lake📍 Maitland Eli Lilly and Company · Tests: LY4006895, Placebo Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia NCT07422779NA1 site📍 Ljubljana Institute of Oncology Ljubljana · Tests: Pembrolizumab, Nivolumab, Ipilimumab JSKN022 in Subjects With Advanced Malignant Solid Tumors NCT07292402Phase 11 site📍 Guangzhou Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Tests: JSKN022 Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor NCT06993571NA1 site📍 Hamburg Universitätsklinikum Hamburg-Eppendorf · Tests: Active-tACS, Sham-tACS, Unlocked-tACS Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. NCT06771609Phase 22 sites📍 Beijing📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Adebrelimab + VEX metronomic chemotherapy + radiotherapy, Adebrelimab + VEX metronomic chemotherapy Serotonin Release in Premotor and Motor PD NCT05516732n/a1 site📍 Exeter University of Exeter · Tests: Positron Emission Tomography (PET) scan using CIMBI-36 tracer, Magnetic Resonance Imaging (MRI) Scan, Positron Emission… A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients NCT06946641Phase 11 site📍 Beijing Shanghai Qilu Pharmaceutical Research and Development Cente… · Tests: QLS12010, Placebo Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers NCT06580574Phase 21 site📍 Beijing Peking University · Tests: PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, Radica… Parkinson's Disease in Type 1 Gaucher Disease NCT07886879n/a1 site📍 New York Icahn School of Medicine at Mount Sinai Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) NCT07132541Phase 11 site📍 Minya Minia University · Tests: Pancreatic parenchymal injection of N-butyl-2-cyanoacrylate(Histoacryl®) A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients NCT06249919Phase 1, Phase 216 sites📍 Bucheon-si📍 Gwangju📍 Ilsan Neuracle Science Co., LTD. · Tests: NS101, Placebo A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729Phase 3246 sites📍 Bakersfield📍 Beverly Hills📍 Stamford Merck Sharp & Dohme LLC · Tests: Calderasib, Placebo, Pembrolizumab Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers NCT05395624Phase 1, Phase 23 sites📍 San Francisco📍 Stanford📍 Jacksonville Ashvattha Therapeutics, Inc. · Tests: 18F-OP-801 Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Vebreltinib, Furmonertinib 80mg The Switching Antiplatelet-9 (SWAP-9) Study NCT06588595Phase 41 site📍 Jacksonville University of Florida · Tests: Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel Clinical Validity of the DANU Sports System for Gait and Balance Assessment in Parkinson's Disease NCT07281794n/a2 sites📍 Newcastle upon Tyne📍 Newcastle upon Tyne Northumbria University Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) NCT03486873Phase 3782 sites📍 Tucson📍 Bakersfield📍 Fresno Merck Sharp & Dohme LLC · Tests: Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280 This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects NCT07304791Phase 11 site📍 London Beam Therapeutics Inc. · Tests: BEAM-103, Placebo Comparator Real-world Patient Experiences With Inbrija® NCT07797790n/a2 sites📍 Altmünster📍 Graz Merz Therapeutics GmbH · Tests: Levodopa inhalation powder Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG NCT06107374Phase 21 site📍 Iowa City CellSight Technologies, Inc. · Tests: [18F]F-AraG Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease NCT07498686n/a2 sites📍 Beijing📍 Beijing Xuanwu Hospital, Beijing A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) NCT05920356Phase 3424 sites📍 Santa Barbara📍 Newark📍 Coral Springs Amgen · Tests: Sotorasib, Pembrolizumab Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors NCT06086522Phase 14 sites📍 Scottsdale📍 New Haven📍 Grand Rapids Qualigen Theraputics, Inc. · Tests: QN-302 Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease NCT07299240NA1 site📍 Nanjing Jiangsu Province Nanjing Brain Hospital · Tests: Remote ischemic conditioning device, Sham remote ischemic conditioning
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy